HOME >> MEDICINE >> NEWS
GSK announces launch of largest ever Phase III trial in lung cancer treatment

Chicago - June 5th, 2007 GlaxoSmithKline (GSK) today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC). These data were presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, [Abstract No: 7554]. Final trial analysis showed a 27% reduction in the relative risk of cancer recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo.

Final results from this trial confirm the positive interim results released last year at ASCO 2006, and support expanded testing of this novel cancer immunotherapy, said Paul A. Bunn Jr., M.D., James Dudley Endowed Professor of Oncology, Professor of Medicine and Director of the University of Colorado Cancer Center, Aurora, Colorado. This approach represents a potentially momentous shift in the cancer treatment paradigm. I believe we have only just scratched the surface of what is possible and look forward to seeing the results of the Phase III trial in due course.

Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3 positive patients with completely resected stage IB, II or IIIA NSCLC.

GSKs ASCIs aim to stimulate the patients own immune response to identify and attack cancer cells in a highly specific manner. This novel cancer immunotherapy is developed using tumor specific antigens, delivered as highly purified recombinant proteins, and GSKs own proprietary Adjuvant Systems, which are specifically designed to enhance ASCIs anti-tumor activity

Phase
'"/>

Contact: Andrea Long
andreal@wagged.com
202-326-0791
GlaxoSmithKline Biologicals
5-Jun-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. AstraZeneca announces SYMBICORT is now available in the US
3. Weill Cornell Medical College announces gifts totaling $400M
4. Elsevier announces launch of Brain Stimulation
5. NSW Premier announces $15M for childrens cancer research
6. National Inventors Hall of Fame announces 2007 inductees
7. Emory University announces new Global Health Institute
8. BioMed Central announces Journal of Medical Case Reports
9. Tibotec Therapeutics announces start of largest US study on HIV treatment in women
10. Wiley announces partnership with NASPGHAN and AASLD
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/12/2019)... ... September 12, 2019 , ... ... and national scale in two recent and well-renowned listing publications, the Inc. 5000 ... businesses for the 2019 year. , Dr. Jeffrey Donaldson, CEO and owner ...
(Date:9/11/2019)... ... September 11, 2019 , ... Global Education Group (Global), ... (CME) provider, is the official accreditor for PAINWeek, the largest US pain conference ... topics, as it has done for the past ten years. In addition, the ...
(Date:9/11/2019)... ... , ... Autopsies don’t lie. They report the causes of death as ... harms the heart. It increases risks of heart attack and death. Autopsies ... damage occurs. , An August 1, 2019 article in U.S. News ...
(Date:9/11/2019)... OAK, Mich. (PRWEB) , ... September 10, 2019 , ... ... The new office is location at 32686 Woodward Ave, Suite 103, Royal Oak, ... mile. , “Our Royal Oak location offers comprehensive women’s health services in a contemporary, ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... critical support to the most vulnerable communities impacted by Hurricane Dorian. , ... South Carolina, the Episcopal Diocese of Georgia, and the Episcopal Farmworker Ministry, Episcopal ...
Breaking Medicine News(10 mins):
(Date:9/14/2019)... ... September 14, 2019 , ... On September 11, 2019, after ... jury in Middlesex County found Johnson & Johnson liable for causing the Plaintiffs’ ... caused by asbestos-containing J&J talc products. , A unanimous jury found ...
(Date:9/12/2019)... LAKE CITY (PRWEB) , ... September 12, 2019 ... ... USA are collaborating to help make the services of CPESN’s clinically integrated network ... providers and payers. CPESN USA’s participating pharmacies provide high quality clinical service ...
(Date:9/11/2019)... , ... September 11, 2019 , ... ... analysis, with many companies developing technologies to evaluate medical images. In fact, image ... understands the approaches the FDA is taking to AI-based image analysis, one will ...
Breaking Medicine Technology:
Cached News: